Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $71 million versus the consensus estimate of $62.9 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.